News

Matrix M is an immune stimulating substance for use in vaccines, antibody production and immunological research. Matrix M was already licensed to Crucell for use in influenza vaccines,

The changes to the label for simvastatin-containing medications are based on the FDA’s review of the results of the seven-year Study of the Effectiveness of Additional Reductions in

APC-100 is an orally available drug and has demonstrated multiple activities in various model systems. Adamis Pharmaceuticals intends to commence APC-100 Phase 1/2a trials in patients who are

Pollinex Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three

MORAb-004 is a humanized monoclonal antibody to endosialin/tumor endothelial marker-1 (TEM-1), which is a protein that is expressed in many human malignancies, and which plays a role in

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture and fill-finish for preclinical and clinical programs for therapeutics that do not have

ASG-22ME is an ADC composed of a fully human antibody directed to Nectin-4, an antigen expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. ASG-5ME currently

Silenor is a low-dose (3 mg and 6 mg) oral tablet formulation of doxepin, indicated to treat insomnia characterized by difficulties with sleep maintenance. As per the terms

So far, the company recruited around 500 patients in the trial, whose primary endpoint is overall survival. Merck Serono Oncology Global Clinical Development Unit senior vice president Oliver